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Abstract 
 
Streptomycetes are known for their inherent ability to produce pharmaceutically relevant 
secondary metabolites. Discovery of medically useful, yet novel compounds has become a 
great challenge due to frequent rediscovery of known compounds and a consequent decline in 
the number of relevant clinical trials in the last decades. A paradigm shift took place when the 
first whole genome sequences of streptomycetes became available, from which silent or 
“cryptic” biosynthetic gene clusters (BGCs) were discovered. Cryptic BGCs reveal a so far 
untapped potential of the microorganisms for the production of novel compounds, which has 
spurred new efforts in understanding the complex regulation between primary and secondary 
metabolism. This new trend has been accompanied with development of new computational 
resources (genome and compound mining tools), generation of various high-quality omics 
data, establishment of molecular tools and other strain engineering strategies. They all come 
together to enable systems metabolic engineering of streptomycetes, allowing more 
systematic and efficient strain development. In this review, we present recent progresses 
within systems metabolic engineering of streptomycetes for uncovering their hidden potential 
to produce novel compounds and for the improved production of secondary metabolites. 
 
Keywords: Biosynthetic gene clusters – Genome mining – Secondary metabolites – 
Streptomycetes – Systems metabolic engineering  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abbreviations: antiSMASH, antibiotics and Secondary Metabolites Analysis Shell; ARC, 
antibiotic-remodeling compound; ARTS, Antibiotics Resistant Target Seeker; BGC, 
biosynthetic gene cluster; Cas9, CRISPR-associated protein; CDA, calcium-dependent 
antibiotic; ChIP, Chromatin ImmunoPrecipitation; CRISPR, Clustered Regularly 
Interspaced Short Palindromic Repeats; dRNA-seq, differential RNA sequencing; EFMA, 
Elementary Flux Mode Analysis; FBA, flux balance analysis; FSEOF, Flux Scanning based 
on Enforced Objective Flux; GARLIC, Global Alignment for natuRaL-products 
chemInformatiCs; GC, gas chromatography; GCF, Gene Cluster Family; GNPS, Global 
Natural Products Social Molecular Networking; GRAPE, Generalized Retrobiosynthetic 
Assembly Prediction Engine; GSMM, genome-scale metabolic models; HR, homologous 
recombination; IMG-ABC, Integrated Microbial Genomes Atlas of Biosynthetic gene 
Clusters; LC-MS/MS, liquid chromatography tandem mass spectrometry; MFA, metabolic 
flux analysis; MIBiG, Minimum Information on Biosynthetic Gene Clusters; MOMA, 
Minimization Of Flux Adjustment; NHEJ, non-homologous end joining; NMR, Nuclear 
magnetic resonance; NRP, non-ribosomal peptide; PAM, protospacer adjacent motif; PI, 
pristinamycin I; PII, pristinamycin II; PK, polyketide; PRISM, Prediction Informatics for 
Secondary Metabolomes; Ribo-seq, ribosome profiling; sgRNA, single guide RNA; SMBP, 
The Secondary Metabolite Bioinformatics Portal; ssRNA-seq, strand-specific RNA 
sequencing; TFR, TetR family transcriptional regulator; WGCNA, weighted correlation 
network analysis 
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1 Introduction 
Streptomycetes are filamentous gram-positive bacteria predominantly found in soil and water 
environments. The bacteria are recognized for their capabilities to produce secondary 
metabolites with clinically relevant applications, some of which include antibiotics such as 
streptomycin and daptomycin, anthelmintic compound avermectin, immunosuppressant 
tacrolimus (FK-506), and anti-cancer agents bleomycin and doxorubicin (for review, see [1]). 
Despite the proven clinical effects of secondary metabolites, drug discovery in streptomycetes 
has witnessed a decline in success rate ever since the golden age of antibiotics experienced 
from late 1940s to 1960s [2]. A paradigm shift begun in the early 2000s when the complete 
genome sequences of a model organism Streptomyces coelicolor [3] and an industrial strain 
Streptomyces avermitilis [4] were published. In the case of S. coelicolor, the 8.6 Mb linear 
chromosome was found to harbor several cryptic or silent biosynthetic gene clusters (BGCs) 
in addition to already known BGCs of actinorhodin, undecylprodigiosin and calcium-
dependent antibiotic (CDA). These silent BGCs showed indications of possible biosynthesis 
of secondary metabolites, but interestingly, no corresponding compounds were detected under 
standard laboratory growth conditions. In the following years, many of these silent BGCs 
were successfully activated and their corresponding secondary metabolites were 
characterized, including iron-chelators desferrioxamine [5] and coelichelin [6,7], 
sesquiterpene antibiotic albaflavenone [8], and polyketide (PK) alkaloid coelimycin [9]. The 
initial successes in identifying novel secondary metabolites from silent BGCs have led to the 
subsequent increases in the genome sequencing of streptomycetes in the last decade (Fig. 1).  
Availability of genome data has spurred advances in relevant technologies covering 
computational resources (in particular, genome and compound mining tools), high-throughput 
(omics) techniques as well as molecular tools. Genome mining tools such as antibiotics and 
Secondary Metabolites Analysis SHell (antiSMASH) [10–12] and Prediction Informatics for 
Secondary Metabolomes (PRISM) [13,14] have greatly improved our ability to survey the 
genomic potential of strains, and allowed for initial prioritization of engineering efforts. Also, 
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omics techniques such as transcriptomics and proteomics have contributed to understanding 
the complex regulatory networks employed by streptomycetes to balance primary and 
secondary metabolism [15,16]. Availability of such genome and expression data has further 
enabled construction of genome-scale metabolic models (GSMMs) of streptomycetes to 
describe metabolic pathways and predict optimal routes for the production of secondary 
metabolites [17]. 
With high-quality whole genome sequences and an array of suitable 
genome/compound mining and molecular cloning tools readily at hand, the secondary 
metabolite research is now moving towards systems metabolic engineering of streptomycetes 
in order to fully harness their potential to produce medically valuable secondary metabolites 
[18]. Systems metabolic engineering brings in recent developments experienced in the fields 
of systems and synthetic biology, and provides a more systematic and efficient approaches for 
strain engineering [19]. However, streptomycetes and other secondary metabolite-producing 
microbes require additional sophisticated analyses concerned with secondary metabolite 
BGCs before strains are engineered at the systems level for the novel compound production 
and the improved production titers [17]. To this end, here we review recent progress within 
the field of systems metabolic engineering of streptomycetes with focuses on the additional 
sophisticated analyses unique to streptomycetes as well as recent successful studies on 
streptomycetes engineering (Fig. 2).  
 
2 Unique considerations for systems metabolic engineering of streptomycetes 
The established framework of systems metabolic engineering [19] can serve as a guideline for 
the optimal production of secondary metabolites using streptomycetes (Fig. 3). However, 
systems metabolic engineering of streptomycetes has additional special considerations that 
are not necessarily relevant to popular model organisms such as Escherichia coli and 
Saccharomyces cerevisiae. In this context, we first focus on these ‘unique considerations’ for 
streptomycetes, including characterization of BGCs, their encoding secondary metabolites 
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and regulations involved in the secondary metabolite biosynthesis as well as molecular tools 
specifically adapted for the streptomycetes engineering. 
 
2.1 Characterization of BGCs and their secondary metabolites through computational 
resources 
Due to the complex nature of secondary metabolism, computational resources are needed to 
better understand working mechanisms of secondary metabolisms many of which are still 
unknown. Secondary metabolite biosynthetic pathways are also not sufficiently covered by 
existing general metabolic databases (e.g., KEGG and MetaCyc). Fortunately, advances in 
high-quality genome sequences of Streptomyces isolates (Fig. 1) and other secondary 
metabolite-producing organisms have sparked the development of such specialized 
computational resources, including databases and genome/compound mining tools, and the 
representative ones are presented herein. First, BGC databases allow for easy access and 
evaluation of curated and predicted BGCs, such as the Minimum Information on Biosynthetic 
Gene Clusters (MIBiG) [20], the Integrated Microbial Genomes Atlas of Biosynthetic gene 
Clusters (IMG-ABC) [21], and the antiSMASH database [22]. For the secondary metabolite 
compounds, several comprehensive databases exist as well, including NORINE [23] 
specifically for non-ribosomal peptides (NRPs), Antibiotic’ome [24] for the predicted 
molecular targets of antibiotics, and StreptomeDB [25], which presents information on 
compounds produced by streptomycetes.   
Second, genome mining tools continue to develop with more features, which allow 
for predicting and assigning functions to enzymes involved in the biosynthesis of secondary 
metabolites. antiSMASH [12] and PRISM [14] are two of the most well-established tools, 
which both base their predictions on identification of signature genes or domains known to be 
specific for secondary metabolite BGCs [20]. Another recently released approach called 
EvoMining employs phylogenomic analysis to identify repurposed enzymes, originating from 
primary metabolism, which has been recruited to secondary metabolism for the secondary 
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metabolite biosynthesis [26]. Using this EvoMining approach, Cruz-Morales et al. identified a 
new clade of biosynthetic enzymes involved in the biosynthesis of arseno-organic metabolites 
[26]. In addition, an alternative way of mining BGCs is found in the Antibiotics Resistant 
Target Seeker (ARTS) (https://arts2.ziemertlab.com), which evaluates BGCs based on self-
resistance mechanisms of antibiotic producers [27]. ARTS scans genomes for promising 
BGCs based on known resistances and the presence of duplicated, co-localized housekeeping 
genes that display an evidence of horizontal gene transfer. In the context of systems metabolic 
engineering, the identified resistance genes can be used as probes to find novel BGCs without 
requiring detailed information on the BGC. The Gene Cluster Family (GCF) network 
(http://www.igb.illinois.edu/labs/metcalf/gcf/index.html) [28] is another useful approach for 
BGC identification, which groups gene clusters and assigns functions of previously 
uncharacterized BGCs. 
For the compound mining, further prioritization of BGCs in promising strains can be 
achieved through cheminformatic analyses of the metabolome data generated from liquid 
chromatography (LC) tandem mass spectrometry (MS/MS) or nuclear magnetic resonance 
(NMR) [13,29]. Upon LC-MS/MS-guided identification of new compounds, following 
compound mining (or cheminformatic) tools enable automated compound characterization 
and dereplication: Global Alignment for natuRaL-products chemInformatiCs (GARLIC) in 
combination with Generalized Retrobiosynthetic Assembly Prediction Engine (GRAPE) 
platform [30]; and the open-access MS/MS database Global Natural Products Social 
Molecular Networking (GNPS) [31]. The GARLIC pipeline allows for both linking orphaned 
products to their corresponding BGCs and for identification of novel compounds by aligning 
bacterial PK and NRP BGCs predicted by PRISM to a comprehensive library of natural 
products from GRAPE [30]. The applicability of this pipeline consisting of PRISM, GRAPE 
and GARLIC was demonstrated by identifying a new compound, potensibactin, isolated from 
Nocardiopsis potens DSM 45234, and also by linking three previously orphaned natural 
products, lucensomycin, octacosaminin and bogorol, to their respective BGCs in 
Streptomyces achromogenes NRRL 3125, Amycolatopsis sp. NAM 50, and Brevibacillus 
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laterosporus DSM 25, respectively. Meanwhile, the GNPS platform contains a 
comprehensive compound data collection curated by the natural product community [31]. As 
this community-driven knowledge-sharing database constantly expands, it allows for 
continuous screening of newly uploaded data sets against the established database. Besides its 
applicability in the discovery and characterization of natural products and their BGCs, the 
network can be used to identify structural analogs of a known molecule as exemplified from 
the analysis of a broad-spectrum antibiotic stenothricin from Streptomyces roseosporus. 
Based on the molecular networking and dereplication features of the platform, GNPS 
identified a subnetwork of five stenothricin analogs produced by Streptomyces sp. DSM5940, 
all with different structural properties compared to the original molecule stenothricin.  
More detailed descriptions beyond these computational resources discussed herein 
can be found from several review papers [32–34]. In addition, to aid scientists within the field 
in prioritizing the individual tools, The Secondary Metabolite Bioinformatics Portal (SMBP) 
at http://www.secondarymetabolites.org was recently launched [35]. For each tool or 
database, SMBP provides the users with links and short descriptions, allowing for quick and 
easy browsing. SMBP can especially be useful for metabolic engineers who plan to produce 
secondary metabolites, but are not familiar with secondary metabolism biochemistry. 
2.2 Characterization of the regulation of secondary metabolites biosynthesis in 
streptomycetes – use of omics techniques as an example 
The data obtained from genome mining often provides little information on the regulation of 
secondary metabolites biosynthesis in streptomycetes. An additional level of information 
from omics techniques can be used to clarify the complex regulations involved [36]. 
Transcriptomics is the most accessible and most frequently adopted omics approach which 
monitors changes in the gene expression levels over a course of time, or as a result of external 
stimuli or genetic manipulation [16]. In this context, Nieselt et al. [37] conducted microarray 
analyses of time-point samples of S. coelicolor M145 taken during a 60 h fermentation, and 
established changes in the expression profiles of clustered genes during the metabolic switch 
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from primary to secondary metabolism. Here, the general change in expression profiles 
observed between the 35 h and 36 h especially marked the metabolic switch, which was an 
interval for the depletion of phosphate from the medium. More recently, multi-omics 
techniques were deployed to determine the transcriptional and translational landscape of S. 
coelicolor M145 using differential RNA-sequencing (dRNA-seq) and strand-specific RNA-
seq (ssRNA-seq) first, followed by ribosome profiling (Ribo-seq) [38]. In particular, the use 
of Ribo-seq shed light on the level of translational control on genes involved in both primary 
and secondary metabolism, and revealed a general decline in the translation efficiency of 
BGCs in S. coelicolor after the cell’s transition to growth phase. Furthermore, translation 
efficiency was negatively correlated with transcription, hence revealing the extra level of 
regulation to account for when embarking on the quest of strain optimization.  
In addition to transcriptomics, proteomics can provide additional and complementary 
information on regulations associated with the transition to antibiotic production. Proteome 
data of S. coelicolor M145 were collected at three developmental stages ranging from 
compartmentalized mycelium (12 h) to the multinucleated mycelium (24 h and 72 h), which 
revealed that hypha differentiation from substrate to aerial hypha was found to be correlated 
with a change in proteome composition [39]. Based on LC-MS/MS, 626 proteins were 
identified, of which 345 proteins were further quantified to reveal that proteins involved in 
primary metabolism were the most abundant in the cells in the compartmentalized mycelium, 
whereas proteins involved in secondary metabolism were found to predominate the cells in 
the multinucleated mycelium. Such omics studies will allow us better understand metabolic 
characteristics and complex regulations involved in biosynthesis of desired secondary 
metabolites. 
2.3 Molecular tools for streptomycetes engineering 
A remarkable progress recently made in the computational field has been accompanied with 
concurrent advances in molecular tools in order to overcome callenges associated with 
streptomycetes engineering: high GC contents, relatively long cultivation times and 
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occasional (or frequent in some strains) reluctance towards introduction of recombinant DNA 
[40]. To circumvent the limitations encountered when using the standard restriction- and 
ligation-based cloning for genetic manipulation, the E. coli-derived λ Red system was applied 
for faster and more efficient gene disruption, in-frame deletion, gene replacement, and 
refactoring of entire gene clusters in Streptomyces strains [41]. To aid genetic engineering 
effort even further in streptomycetes, an alternative to this classical method was reported 
using the S. cerevisiae I-SceI homing endonuclease for DNA double strand break (DSB)-
based genome editing [42,43]. This meganuclease differs from conventional restriction 
enzymes by its longer recognition site of 18 bp and with a lower risk of off-targets for gene 
editing purposes. Using a two-plasmid system, the I-SceI recognition sequence and a suitable 
resistance marker are introduced into a defined site on the genome of the recipient 
streptomycete via a single crossover event using the first plasmid. Double crossover is 
induced upon introduction of the second plasmid, which harbors the synthetic codon-
optimized I-SceI under the control of either the constitutive ermE* or thiostrepton-inducible 
tipA promoter. To facilitate marker-free gene deletions, plasmids derived from pSG5 [44] 
with temperature sensitive replicons can be used. When using the I-SceI system for gene 
replacement in Streptomyces sp. Tü 6071, I-SceI-mediated homologous recombination (HR) 
was found to be 25 times more efficient than spontaneously occurring HR, hence, establishing 
its use for more systematic gene editing in streptomycetes [42].   
More recently, an even more efficient and flexible system for genome engineering in 
streptomycetes has made its way to the field, namely the type II Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated protein (Cas9) system 
from Streptococcus pyogenes. The CRISPR-Cas9 technique can be applied for deletion of 
genes and gene clusters [45–47] in a multiplex manner [45], reversible gene expression 
control [47], and induction [48]. The optimized system relies on two components: the single 
guide RNA (sgRNA), which is a synthetic RNA consisting of a CRISPR RNA (crRNA) and 
trans-activating crRNA (tracrRNA) complex, and is required for guiding Cas9 to modify the 
targeted genome sequence; and the endonuclease Cas9 or catalytically inactive dCas9, which 
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upon interaction with the sgRNA, scans the genome for protospacer adjacent motif (PAM) 
sequences and the corresponding 20 bp recognition site. Upon recognition of the target DNA 
sequence, Cas9 binds to and cleaves the specific site in the genome whereas the inactive 
dCas9 will bind to the target DNA without sequence modifications. Here, the dCas9 presents 
an easy-to-clone tool for reversible control of gene expression, and thus is useful for 
investigating regulation without the risk of off-target effects or subjecting the cells to the 
stress associated with gene replacements or mutagenesis procedures [47]. CRISPR-Cas9-
mediated mutagenesis can be used in the absence of templates for HR. In this case, the repair 
mechanism is dependent on the non-homologous end joining (NHEJ) of the DNA in 
Streptomyces species. However, efficiency and specificity are greatly improved if a homology 
template for HR is provided [45–47]. This has been demonstrated in independent studies, in 
which Cobb et al. [45] and Huang et al. [46] reported 60%~100% and 70%~100% 
efficiencies, respectively, whereas Tong et al. [47] reported near 100% efficiency for their 
studies on the actinorhodin gene cluster in S. coelicolor. 
For specific applications, the CRISPR-Cas9 system has proven suitable for 
identification and examination of putative genes and BGCs for secondary metabolism in 
several Streptomyces species. One example is the use of the system for discovery and 
examination of the BGC encoding the antibiotics formicamycins in a new isolate 
Streptomyces formicae [49]. Using the pCRISPomyces-2 vector, which harbors both the 
codon-optimized Cas9 from S. pyogenes and the sgRNA cassette, the only type II polyketide 
synthase (PKS) BGC in S. formicae was deleted, resulting in a mutant incapable of producing 
any formicamycins. Using the same vector, the authors proceeded to elucidate the 
biosynthetic pathway by knocking out single genes in the putative BGC, and ultimately 
proposed a preliminary biosynthetic route for the production of this group of antibiotics [49]. 
Similarly, CRISPR-Cas9 was used to determine that the LuxR family cluster-situated 
regulator FscRI was necessary for the activation of antimycins biosynthesis in Streptomyces 
albus S4 [50]. Using this information, heterologous production of antimycins in S. coelicolor 
M1146 was achieved when the BGC was co-expressed with its activator FscRI. The general 
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versatility of the CRISPR-Cas9 system has been further exemplified by its application for 
genome editing of rare actinomycetes, one of which is Actinoplanes sp. SE50/110 [51]. 
The CRISPR-Cas9 was applied in an alternative fashion for the knock-in strategy in 
order to activate silent BGCs in multiple Streptomyces strains [48]. Replacing native 
promoters with the strong, constitutive promoter kasOp* using the CRISPR-Cas9 system led 
to the production of new compounds in S. roseosporus, Streptomyces venezuelae, and 
Streptomyces viridochromogenes. Furthermore, the compound isolated from S. 
viridochromogenes was found to be a novel pigmented PK produced from an otherwise silent 
BGC of the type II PKS. Although this activation strategy bears striking similarity to a 
technique previously reported for the activation of five gene clusters in S. albus J1074 [52], 
the incentive to use the CRISPR-Cas9 system is the increased efficiency of HRs, presenting 
an improved method for genetic manipulation of strains suffering from the low efficiency of 
natural recombination. 
 The use of synthetic or natural strong promoters has also been proven useful in 
activating BGCs with low or no expression levels [53–55]. Based on the xylE reporter gene 
and RNA-seq, 32 promoters from S. albus J1034 were identified and characterized, revealing 
ten promoters with strengths 200%~1,300% higher than that reported for the standard, 
constitutive promoter ermE*p [55]. Using a similar screening approach, Siegl et al. [54] 
evaluated their collection of synthetic promoters, and reported strengths of 2%~319% in 
comparison with that of ermE*p. 
In addition to the newly adapted molecular tools discussed above, various systems 
metabolic engineering strategies for the model organisms can also be deployed to refactor 
secondary metabolites biosynthesis in native hosts, including removal of competing pathways 
to change the flux distribution or increase the pool of precursors, deletion of repressors, and 
overexpression of activators [56]. With further advances in the field, systems metabolic 
engineering strategies will also be employed for establishment and optimization of secondary 
metabolites production in heterologous hosts in the future (see below). 
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2.4 Additional approaches that facilitate streptomycetes engineering 
Besides the molecular tools discussed above, several additional approaches exist, which may 
further facilitate streptomycetes enginering and the secondary metabolite production. First, if 
the native host is reluctant towards any genome engineering efforts, heterologous expression 
might prove a helpful alternative [40,57]. Strains such as S. albus, S. avermitilis, S. coelicolor 
and Streptomyces lividans are readily amenable to cloning and expression, and therefore, their 
use as heterologous hosts circumvents native host limitations [58]. Also, the construction of 
genome-minimized hosts, which have had one or more BGCs removed from their genomes, 
might improve titers of a given product by avoiding the use of common precursors for other 
secondary metabolites [56,58]. One such example is the minimized host S. coelicolor M1154 
which had four of its BGCs deleted in addition to the introduction of point mutations in rpoB 
and rpsL, and is known to have an improved antibiotic production performance. Using this 
host, Gomez-Escribano and Bibb reported 30- and 40-fold increases in the production titers of 
congocidine and chloramphenicol, respectively, compared to the control strain S. coelicolor 
M145 as the production host [59]. An even further reduction of the S. coelicolor genome was 
obtained by Zhou et al. [60] who, using PCR-targeting of cosmids for the gene disruption, 
sequentially deleted all the ten BGCs encoding PKS and non-ribosomal peptide synthetases 
(NRPS) in addition to a 900-kb subtelomeric region. A series of mutants were generated as a 
result, one of which had 14% of its genome deleted. Furthermore, a physiological comparison 
of the constructed genome-minimized mutants to the wild-type showed no differences in 
growth rates. Hence, this strategy can provide new hosts suitable for heterologous expression 
of a wide variety of BGCs.  
The development of a small molecule activation approach could also prove helpful 
when working with the troublesome isolates. In this regard, chemical elicitation which uses 
small molecules to induce the metabolites production in a given strain has been used with 
positive outcomes [61,62]. Using the GFP- and LacZ-based reporter systems to monitor 
activation of gene expression, a library of 640 elicitors was screened to find nine of them 
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eliciting production of two otherwise silent BGCs in Burkholderia thailandensis E264 [61]. 
Similarly, in a study on the effects of rare earth elements on secondary metabolite production 
in S. coelicolor, scandium and lanthanum were found to induce gene expression for the 
actinorhodin BGC in addition to four otherwise silent BGCs [63]. More recently, a library of 
30,569 small molecules was screened for their effects on actinorhodin production in S. 
coelicolor M145 [64]. This led to the isolation of a group of four antibiotic-remodeling 
compounds (ARCs), of which ARC2 was found capable of eliciting secondary metabolism in 
related Streptomyces species as well. Following these findings, the synthetic derivative Cl-
ARC was used for the stronger elicitation of BGCs encoding molecules at a low abundance in 
a panel of fifty Actinomycete strains [65]. This resulted in the identification of several CI-
ARC-induced compounds including oxohygrolidin from Streptomyces ghanaensis, not 
previously known to produce this molecule [66]. Furthermore, based on bioactivity-guided 
assays, it was shown that while the extracts of the elicitor-treated S. ghanaensis failed to 
provide detectable inhibition, purified oxohydrolidin displayed activity against S. cerevisiae 
Y7092. The latter finding provides strong incentives to focus future work on purified 
compounds in order to avoid masking of low abundance molecules in complex sample 
mixtures. Furthermore, such systematic analyses show a great promise in high-throughput 
screening approaches in that they allow for both screening multiple elicitors on one strain, or, 
as reported by Craney et al. [64], screening one elicitor molecule against a collection of 
strains. The major limitation to such an approach, however, remains in the massive amount of 
samples generated, which all require time-consuming subsequent analytics studies. 
 
3 Recent examples of systems metabolic engineering of streptomycetes for the optimized 
production of secondary metabolites 
The framework of systems metabolic engineering continues to be adopted to improve the 
production of secondary metabolites in streptomycetes, as seen from the many recent 
successful examples reported (Table 1). Some noteworthy examples include the production of 
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tacrolimus (FK506) using Streptomyces tsukubaensis [67–69], ascomycin (FK520) using 
Streptomyces hygroscopicus var. ascomyceticus [70–72], avermectin using S. avermitilis [73], 
and pristinamycin I (PI) and II (PII) using Streptomyces pristinaespiralis  [74,75]. 
To solve the issue of low production yield of tacrolimus in the natural producer, 
Wang et al. [67] first determined the intracellular response of S. tsukubaensis to exogenous 
feeding of four precursors known to promote the tacrolimus biosynthesis. Using a weighted 
correlation network analysis (WGCNA) on a dataset containing 93 different intracellular 
metabolites measured with gas chromatography (GC)-MS and LC-MS/MS, metabolites 
highly associated with the tacrolimus biosynthesis were identified. Furthermore, time-point 
sampling led to the identification of three pronounced pathways involved in the tacrolimus 
biosynthesis, namely pentose phosphate, shikimate, and aspartate pathways. Using this 
information and the GSMM of S. tsukubaensis, the genes aroC and dapA, involved in the 
biosynthesis of chorismate and lysine, respectively, were identified for overexpression, and 
the effects of overexpression of these genes were experimentally validated. As a result, a 
mutant overexpressing the aroC and dapA genes produced 1.64-fold higher yields of 
tacrolimus, compared to the wild-type strain.  
Ascomycin, an ethyl analog of tacrolimus, is another important immunosuppressant. 
To optimize the production of this compound, the natural producer S. hygroscopicus var. 
ascomyceticus has undergone several rounds of metabolic engineering. Early strain 
development efforts have so far included femtosecond laser irradiation mutagenesis combined 
with a shikimic acid enduring screening. Although shikimic acid was found to have a positive 
effect on the ascomycin production, the mutant strain FS35, from the mutagenesis screen, also 
displayed high sensitivy towards this substrate. To overcome this negative effect, an 
endurance screening with shikimic acid was carried out, resulting in the isolation of a 
shikimic acid-resistant mutant strain SA68 with ascomycin yield of 330 mg/L (270 mg/L for 
the parent strain) [70,71]. More recently, systems metabolic engineering [72] was employed 
to obtain a high-yield ascomycin producing strain, which showed 84.8% titer improvement, 
compared to the parent strain. Prior to the strain engineering, 13C-labelling experiments and 
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metabolic flux analysis (MFA) were employed in parallel to construct and validate an 
ascomycin metabolic network. Elementary flux mode analysis (EFMA) on the model allowed 
the identification of chorismatase FkbO and pyruvate carboxylase Pyc as overexpression and 
inactivation targets, respectively. Furthermore, from the fed-batch fermentation of the high-
producer strain TD-ΔPyc-FkbO, ethylmalonyl-CoA was found to be limited towards the end 
of fermentation, which opens up for future engineering efforts.   
Similarly, industrial producer strains have undergone extensive systems metabolic 
engineering to improve their production titers of a group of avermectins [73]. As avermectin 
biosynthesis is under the tight control of several regulators, much focus has been put on 
relieving such regulators. The pathway-specific regulator AveR, which is involved in the 
activation of avermectin biosynthesis, is itself subject to both negative and positive regulation 
[73]. Here, the two TetR family transcriptional regulators (TFRs) encoded by the genes 
SAV576 and SAV577 were found to indirectly downregulate the avermectin biosynthesis 
through binding to the promoter region of SAV575; SAV575 is known to be involved in 
providing acetate and propionate extender units required for the avermectin production 
[76,77]. Using a combination of microarray analysis, genetic studies, and chromatin 
immunoprecipitation (ChIP) assays, the expression levels of the TFRs and SAV575 were 
determined for both mutant and wild-type strains as well as the binding sites of SAV575 for 
the TFRs. This observation allowed for proposing the regulatory role of the TFRs in the 
avermectin production. Based on this information, a double deletion mutant (∆SAV576 and 
∆SAV577) was constructed, which showed ~3 fold higher production of avermectin, 
compared to the wild-type [77]. 
A more recent example of using a combinatorial metabolic engineering approach has 
been presented for the production of streptogramin-like antibiotic pristinamycin, which 
consists of two chemically unrelated compounds PI and PII [78]. As the native host S. 
pristinaespiralis suffers from low yields, additional copies of the two BGCs responsible for 
the production of PI and PII were introduced in addition to the deletion of repressors [74,75]. 
The metabolic engineering efforts were strongly aided from previous findings of the 
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regulatory cascade governing the biosynthesis of both PI and PII in S. pristinaespiralis [79]. 
For PII, the deletion of the two cluster-specific repressors PapR3 and PapR5 along with 
overexpression of the activators PapR4 and PapR6 resulted in a 1.5-fold higher production of 
PII in a mutant harboring an additional copy of the PII BGC, compared to the wild-type. 
Furthermore, the addition of resins to relieve both feedback inhibition and toxicity of PII 
resulted in the 5.26-fold higher production, compared to wild-type, when grown in 5 L 
bioreactors [74]. For PI, the highest production was observed in a mutant in which the BGC 
of PII was removed, an additional copy of the PI BGC introduced, and the repressor PapR3 
deleted. Besides the 2.4-fold increased production of PI compared to the wild-type, 
interestingly, the mutant with only the PII BGC removed showed 20-40% lowered PI 
production, compared to the wild-type, revealing a possible role of PII as a coactivator or 
inducer of PI production [75]. Further characterization efforts are needed to unravel the 
regulatory mechanism behind this observation and to additionally engineer the strain 
accordingly.    
Additional examples on the use of both metabolic engineering and more general 
engineering strategies for the optimization of secondary metabolites production in 
actinobacteria have recently been reviewed elsewhere [56].  
 
4 Conclusions 
The expansions and improvements witnessed within the fields of genome and compound 
mining, omics, and molecular cloning techniques are paving the way for systems metabolic 
engineering to harness the production potential of streptomycetes. Systematic and global 
analyses that have been undertaken will continue to improve, and, as a result, will foster faster 
and better decision making when re-designing a given strain for the optimal production of a 
target secondary metabolite and discovery of new secondary metabolites. However, it should 
be noted that, despite all these resources available, a certain amount of iterations of the 
design-build-test-learn cycle are still necessary as demonstrated for other microbial metabolic 
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engineering cases, especially taking into account the complex regulation between primary and 
secondary metabolism in streptomycetes. Implementation of molecular cloning methods in an 
automated, high-throughput setting, such as iBioFab [80], biosensors for detecting expression 
of secondary metabolite biosynthesis genes [81], or biosensors for the production of a desired 
secondary metabolite [82] might further reduce time and efforts needed to optimize the 
production of secondary metabolites using streptomycetes. It is expected that the tools and 
strategies of systems metabolic engineering of streptomycetes will advance rapidly to harness 
full biotechnological potentials of this important class of bacteria. 
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Tables 
Table 1 Examples of metabolic engineering strategies used for the optimization of secondary metabolite production in streptomycete hosts 
Secondary metabolite Streptomyces host Metabolic engineering strategies 
Highest yield 
increase 
(compared to 
control strain) 
References 
Actinorhodin Streptomyces coelicolor A3(2) 
• Construction of two comprehensive GSMMs: iIB711 and iMK1208. The latest 
iMK1208 comprises 1208 genes, 1643 reactions, and 1246 metabolites 
• Construction of a mutant strain with improved yields 
• 13C-MFA and transcriptional analysis of mutant and parental strains to compare 
their fluxes and gene expression patterns, respectively 
• FSEOF on iMK1208 to identify additional gene target for overexpression and 
subsequent experimental verification 
52-fold  [83–85] 
Ascomycin Streptomyces hygroscopicus var. ascomyceticus 
• Parallel 13C labeling and MFA to construct metabolic network model 
• EFMA on the ascomycin network model for target predictions 
• Strain engineering by overexpression and inactivation of genes 
• Addition of resin HP20 in the growth medium 
84.8% [70–72] 
Avermectin Streptomyces avermitilis 
• Increasing flux through precursor pathways 
• Microarray analysis and ChIP assays for the analysis of expression levels 
• Identification and deletion of regulators with inhibitory effect on production 
3-fold [73,76,77] 
Daptomycin Streptomyces roseosporus LC-511 
• MFA to identify potential bottlenecks in biosynthesis 
• Identification of three genes for overexpression to increase fluxes through rate-
limiting pathway 
• Construction of a triple overexpression mutant with improved titers 
• Transcriptional analysis to evaluate gene expression patterns of parental and 
mutant strains 
• Addition of glucose to fed-batch fermentations of the triple mutant strain to 
improve yields further 
43.2% [86,87] 
Pristinamycin Streptomyces pristinaespiralis 
• Transcriptional analysis by RT-PCR for the evaluation of regulatory network 
involved in biosynthesis 
• Strain engineering by introduction of extra copies of the BGC, deletion of 
repressors, and overexpression of activators 
• Addition of resins to bioreactors 
2.4-fold (PI) 
5.26-fold (PII) [74,75] 
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Rapamycin Streptomyces hygroscopicus ATCC 29253 
• Construction of a GSMM with 1003 reactions and 711 metabolites 
• FBA and MOMA analyses to evaluate gene targets for improving production 
• Construction of a mutant strain with one gene knock-out and overexpression of 
two genes showing higher fluxes through key primary metabolism pathways 
142.3% [88] 
Spinosad Streptomyces albus J1074 
• Construction of a Saccharopolyspora spinosa NRRL 18395 bacterial artificial 
chromosome library 
• Establishment of heterologous expression of spinosyn BGC in Streptomyces 
lividans TK24 and S. albus J1074 
• Transcriptional and translational (proteomics) analyses to evaluate heterologous 
and native hosts 
• Metabolomics to identify the best suited candidate host for the expression of 
spinosyn BGC 
• Pathway refactoring including promoter engineering and overexpression of 
synthetic modules in S. albus mutant 
1000-fold [89]  
Tacrolimus Streptomyces tsukubaensis 
• Proteomic and metabolomic analyses of an overproducer strain fed with soybean 
oil 
• WGCNA for the identification of pronounced precursor pathways 
• Identification of key limiting steps in the pronounced pathways using a GSMM 
• Gene overexpression to increase fluxes through two precursor pathways 
1.64-fold [67–69] 
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Figure legends 
 
Figure 1.  Cumulative number of whole genome sequences of Streptomyces species published in National Center for Biotechnology Information (NCBI) 
from 2001 to September 2017. 
 
Figure 2. Schematic representation of the workflow of systems metabolic engineering for streptomycetes. Characterization of BGCs, their encoding 
secondary metabolites and biosynthesis regulations involved is critical in engineering streptomycetes for the production of novel compounds and the higher 
yields of a known end product or. Genome and compound mining, omics techniques, molecular tools as well as the use of elicitors play important roles in this 
process.  
 
Figure 3. Workflow of systems metabolic engineering for the optimal production of secondary metabolites. The workflow shown includes tools and methods 
used within the individual steps. The workflow can be applied in an iterative fashion as illustrated by the design-build-test-learn cycle. The use of the entire 
workflow is exemplified by the production of ascomycin using Streptomyces hygroscopicus var. ascomyceticus. Here, (1) and (2) illustrates the two separate 
rounds of engineering applied for the optimization of ascomycin production.  
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